Kopran Limited (IN:KOPRAN)
:KOPRAN
Want to see IN:KOPRAN full AI Analyst Report?
KOPRAN Stock Chart & Stats
₹152.20
-₹3.64(-1.71%)
At close: 4:00 PM EST
₹152.20
-₹3.64(-1.71%)
Day’s Range― - ―
52-Week Range₹107.00 - ₹218.90
Previous CloseN/A
Volume53.95K
Average Volume (3M)13.07K
Market Cap
₹8.76B
Enterprise Value₹11.41B
Total Cash (Recent Filing)₹372.08M
Total Debt (Recent Filing)₹1.57B
Price to Earnings (P/E)34.1
Beta1.54
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.96%
Share Statistics
EPS (TTM)3.65
Shares Outstanding48,285,606
10 Day Avg. Volume27,236
30 Day Avg. Volume13,071
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)0.98
Price to Sales (P/S)0.77
P/FCF Ratio-49.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Business Model (APIs, Formulations, Contract Manufacturing)Kopran's mix of finished dosage formulations, APIs and contract manufacturing creates multiple revenue channels and market exposures. This structural diversification reduces reliance on any single product or geography, supporting revenue resilience and strategic flexibility over the next 2–6 months.
Consistent Revenue Growth With FY2026 AccelerationSustained top-line growth and a notable FY2026 acceleration indicate improving demand or better commercial execution. Persistent revenue momentum expands operating scale, supports margin recovery potential, and underpins capacity and investment decisions over a multi-month horizon.
Reasonably Conservative Balance Sheet And Rising EquityModerate leverage and growing equity provide financial headroom to fund working capital and capex without immediate stress. A conservative capital structure enhances resilience to shocks and gives management optionality to fund growth or refinance if cash generation improves.
Bears Say
Persistent Negative Free Cash FlowSustained negative free cash flow points to heavy capex or working-capital drag that erodes internal funding. Over months this reduces financial flexibility, increases dependence on external financing, and constrains the company's ability to deleverage, pay dividends, or fund strategic initiatives.
Volatile Profitability And Uneven MarginsEarnings and margin volatility make cash flows and return expectations less predictable. Structural unpredictability can hamper reinvestment planning, weaken negotiating power with customers, and elevate execution risk for strategic programs over the medium term if margins do not stabilize.
Rise In Total Debt In FY2025–FY2026 Is A Watch ItemAn upward debt trend, if sustained while cash flow remains weak, could shift the balance-sheet profile from conservative to pressured. Increased interest and amortization burdens would reduce free cash flow and strategic flexibility, particularly if earnings and FCF do not recover.
Kopran Limited News
KOPRAN FAQ
What was Kopran Limited’s price range in the past 12 months?
Kopran Limited lowest stock price was ₹107.00 and its highest was ₹218.90 in the past 12 months.
What is Kopran Limited’s market cap?
Kopran Limited’s market cap is ₹8.76B.
When is Kopran Limited’s upcoming earnings report date?
Kopran Limited’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were Kopran Limited’s earnings last quarter?
Kopran Limited released its earnings results on May 19, 2026. The company reported ₹3.91 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.91.
Is Kopran Limited overvalued?
According to Wall Street analysts Kopran Limited’s price is currently Overvalued.
Does Kopran Limited pay dividends?
Kopran Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of 1.96%. See more information on Kopran Limited dividends here
What is Kopran Limited’s EPS estimate?
Kopran Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kopran Limited have?
Kopran Limited has 48,285,606 shares outstanding.
What happened to Kopran Limited’s price movement after its last earnings report?
Kopran Limited reported an EPS of ₹3.91 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.426%.
Which hedge fund is a major shareholder of Kopran Limited?
Currently, no hedge funds are holding shares in IN:KOPRAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kopran Limited
Kopran Limited is a fully integrated pharmaceutical entity that manufactures and distributes both active pharmaceutical ingredients (APIs) and finished drug products, serving markets in India and worldwide. Its extensive product portfolio includes a diverse array of dosage formats, such as tablets, capsules, dry powders, suspensions, and injectable solutions. The company's active pharmaceutical ingredients cater to a broad spectrum of therapeutic applications, encompassing macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, antihistamines, anti-acne treatments, anti-infectives, urologicals, anti-thrombotics, antidiabetics, pain management, gastroenterology, and cardiovascular medications. Established in 1958, Kopran Limited maintains its corporate headquarters in Mumbai, India.
Technical Analysis
Cipla Ltd
―
Marksans Pharma Limited
―
NGL Fine-Chem Ltd.
―
Sanofi India Limited
―
SMS Pharmaceuticals Limited
―